Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Executive Vice President | February 28, 2026 | March 02, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director · President and CEO | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
THERMO FISHER SCIENTIFIC INC.
Report date February 28, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,151.304 |
Ending reported balance
After 2026-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-28 · Tax withholding · Disposed 836.88 · Balance 85,511.029 Row 2 · 2026-02-28 · Tax withholding · Disposed 359.725 · Balance 85,151.304 |
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.45 · Expires 2036-04-30 | Direct | 2,866 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 2,866 · Balance 2,866 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
WEST PHARMACEUTICAL SERVICES INC
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.75 · Expires 2036-09-08 | Direct | 13,879 |
Reported balance
After 2026-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-08 · Grant · Acquired 13,879 · Balance 13,879 F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.75 · Expires 2036-09-08 | Direct | 11,081 |
Reported balance
After 2026-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-08 · Grant · Acquired 11,081 · Balance 11,081 F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.75 · Expires 2036-09-08 | Direct | 12,088 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Grant · Acquired 12,088 · Balance 12,088 F2: This award cliff vests on September 8, 2031. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 6,200 |
Reported balance
After 2026-09-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-08 · Grant · Acquired 6,200 · Balance 6,200 F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 4,950 |
Reported balance
After 2026-09-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-08 · Grant · Acquired 4,950 · Balance 4,950 F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 3,600 |
Reported balance
After 2026-09-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-08 · Grant · Acquired 3,600 · Balance 3,600 F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: This award cliff vests on September 8, 2031. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests in four equal annual installments beginning on September 8, 2027.
F2: This award cliff vests on September 8, 2031.
F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Patheon N.V.
Report date August 29, 2017 · Filed August 31, 2017
Section 16 reporting ended · disclosed 2017-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 1
1 source rowRow 1 · 2017-08-29 · Other · Disposed 245,939 · Balance 0 F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4: This amount includes 201,199 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.49 | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-29 · Disposition to issuer · Disposed 110,402 · Balance 0 F5: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6) F6: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2)
F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3)
F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer.
F4: This amount includes 201,199 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer.
F5: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6)
F6: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 19:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001518973-26-000007 · wk-form4_1789069215.xml · derivative · entry 6 Lagarde Michel · CIK 0001518973 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2 · derivative.exercise_date: This award cliff vests on September 8, 2031. F2 · derivative.expiration_date: This award cliff vests on September 8, 2031. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 19:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 4,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001518973-26-000007 · wk-form4_1789069215.xml · derivative · entry 5 Lagarde Michel · CIK 0001518973 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,950 Underlying: Common Stock · 4,950 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on September 8, 2027. F1 · derivative.expiration_date: This award vests in four equal annual installments beginning on September 8, 2027. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 19:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001518973-26-000007 · wk-form4_1789069215.xml · derivative · entry 4 Lagarde Michel · CIK 0001518973 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on September 8, 2027. F1 · derivative.expiration_date: This award vests in four equal annual installments beginning on September 8, 2027. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 19:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 12,088 | $0.00 Strike: $337.75 | $0.00 |
DisclosureSEC source: 0001518973-26-000007 · wk-form4_1789069215.xml · derivative · entry 3 Lagarde Michel · CIK 0001518973 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,088 Underlying: Common Stock · 12,088 shares Expires 2036-09-08 F2 · derivative.exercise_date: This award cliff vests on September 8, 2031. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 19:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 11,081 | $0.00 Strike: $337.75 | $0.00 |
DisclosureSEC source: 0001518973-26-000007 · wk-form4_1789069215.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,081 Underlying: Common Stock · 11,081 shares Expires 2036-09-08 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on September 8, 2027. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 19:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 13,879 | $0.00 Strike: $337.75 | $0.00 |
DisclosureSEC source: 0001518973-26-000007 · wk-form4_1789069215.xml · derivative · entry 1 Lagarde Michel · CIK 0001518973 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,879 Underlying: Common Stock · 13,879 shares Expires 2036-09-08 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on September 8, 2027. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 2,866 | $0.00 Strike: $424.45 | $0.00 |
DisclosureSEC source: 0000875320-26-000181 · wk-form4_1778015211.xml · derivative · entry 1 Lagarde Michel · CIK 0001518973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,866 Underlying: Common Stock · 2,866 shares Expires 2036-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 21:10 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 359.725 | $521.11 | $187,456.29 |
DisclosureSEC source: 0000097745-26-000047 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,151.304 Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 21:10 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 836.88 | $521.11 | $436,106.54 |
DisclosureSEC source: 0000097745-26-000047 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,511.029 Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:11 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 2,231 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-26-000036 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,347.909 F1 · shares: Shares represent a performance-based restricted stock unit award granted on February 19, 2025. On February 25, 2026, the Compensation Committee certified achievement of the applicable performance criteria. The award vests in three equal tranches on February 28, 2026, 2027 and 2028, in accordance with the terms of the award agreement. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:40 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,637 | $0.00 Strike: $105.17 | $0.00 |
DisclosureSEC source: 0000097745-25-000180 · form4.xml · derivative · entry 5 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,637 shares Expires 2026-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in two equal installments on August 29, 2017 and 2020. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:40 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,046 | $0.00 Strike: $132.66 | $0.00 |
DisclosureSEC source: 0000097745-25-000180 · form4.xml · derivative · entry 4 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,046 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in three equal installments on March 23, 2018, 2019 and 2020. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:40 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 22,046 | $563.56 | $12,424,243.76 |
DisclosureSEC source: 0000097745-25-000180 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,116.909 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.38 to $564.20, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:40 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 22,046 | $132.66 | $2,924,622.36 |
DisclosureSEC source: 0000097745-25-000180 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,162.909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:40 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 18,637 | $105.17 | $1,960,053.29 |
DisclosureSEC source: 0000097745-25-000180 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,116.909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,000 | $0.00 Strike: $105.17 | $0.00 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · derivative · entry 7 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,637 Underlying: Common Stock · 68,000 shares Expires 2026-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal installments on August 29, 2017 and 2020. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 2,521 | $584.11 | $1,472,541.31 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · nonDerivative · entry 5 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,479.909 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.00 to $584.533, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 29,479 | $583.33 | $17,195,985.07 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · nonDerivative · entry 4 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000.909 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.03 to $583.96, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 68,000 | $105.17 | $7,151,560.00 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,479.909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $105.17 | $0.00 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · derivative · entry 6 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,637 Underlying: Common Stock · 36,000 shares Expires 2026-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal installments on August 29, 2017 and 2020. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 30,000 | $581.92 | $17,457,600.00 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,479.909 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.90 to $582.33, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 36,000 | $105.17 | $3,786,120.00 |
DisclosureSEC source: 0000097745-25-000178 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,479.909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:47 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,638 | $0.00 Strike: $253.99 | $0.00 |
DisclosureSEC source: 0000097745-25-000166 · form4.xml · derivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,638 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in four equal installments on February 26, 2020, 2021, 2022, and 2023. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:47 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 4,638 | $594.42 | $2,756,919.96 |
DisclosureSEC source: 0000097745-25-000166 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,479.909 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $594.36 to $594.88, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:47 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 4,638 | $253.99 | $1,178,005.62 |
DisclosureSEC source: 0000097745-25-000166 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,117.909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 21:48 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 161.974 | $489.74 | $79,325.15 |
DisclosureSEC source: 0000097745-25-000125 · form4.xml · nonDerivative · entry 4 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,479.909 Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 21:48 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 275.113 | $489.74 | $134,733.84 |
DisclosureSEC source: 0000097745-25-000125 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,641.883 Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 21:48 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 262.058 | $489.74 | $128,340.28 |
DisclosureSEC source: 0000097745-25-000125 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,916.996 Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 21:48 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 262.058 | $489.74 | $128,340.28 |
DisclosureSEC source: 0000097745-25-000125 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,179.054 Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 2,398 | $0.00 Strike: $502.97 | $0.00 |
DisclosureSEC source: 0000875320-25-000179 · wk-form4_1746476447.xml · derivative · entry 1 Lagarde Michel · CIK 0001518973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,398 Underlying: Common Stock · 2,398 shares Expires 2035-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:28 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 1,125.416 | $528.96 | $595,300.05 |
DisclosureSEC source: 0001127602-25-007924 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,441.112 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:28 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 432.976 | $528.96 | $229,026.98 |
DisclosureSEC source: 0001127602-25-007924 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,566.528 F1 · balance_after: Reflects a downward adjustment of 633 shares of a performance-based restricted stock unit award granted on February 23, 2022. On February 22, 2023, the reporting person reported the acquisition of the performance-based restricted stock unit award. One-third of the shares vested on February 28, 2023, one-third of the shares vested on February 28, 2024, and the remaining one-third vested on February 28, 2025, subject to adjustment based on the Company's relative total shareholder return ("TSR") over the measurement period starting on January 1, 2022, through to December 31, 2024. As a result of the Company's relative TSR, the third tranche was adjusted downward by 30%. As such, the reporting person received 633 less shares than the amount initially reported. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:25 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 13,666 | $0.00 Strike: $530.86 | $0.00 |
DisclosureSEC source: 0001127602-25-006243 · form4.xml · derivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,666 Underlying: Common Stock · 13,666 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:25 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 7,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006243 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,632.504 F1 · shares: Shares represent a performance-based restricted stock unit award granted on February 21, 2024. The Company's Compensation Committee determined on February 19, 2025, that the performance criteria related to this award were satisfied. One-third of the shares vest on February 28, 2025 and 2026. The remaining one-third will vest on February 28, 2027, and is subject to adjustment (positive or negative) for long-term performance which is based on the comparison of the Company's total shareholder return compound annual growth rate ("CAGR") to the total shareholder return CAGR of each of the companies in the peer group, as specified within the award agreement, over the measurement period starting on January 1, 2024, through to December 31, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:25 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 2,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006243 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,214.504 Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:23 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 165.357 | $613.14 | $101,386.99 |
DisclosureSEC source: 0001127602-24-023151 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,983.504 Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:23 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 219.026 | $613.14 | $134,293.60 |
DisclosureSEC source: 0001127602-24-023151 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,148.861 Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:23 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 262.058 | $613.14 | $160,678.24 |
DisclosureSEC source: 0001127602-24-023151 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,367.887 Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 20:11 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 504.29 | $606.12 | $305,660.25 |
DisclosureSEC source: 0001127602-24-022979 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,629.945 Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:16 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $105.17 | $0.00 |
DisclosureSEC source: 0001127602-24-015444 · form4.xml · derivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,637 Underlying: Common Stock · 20,000 shares Expires 2026-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in two equal installments on August 29, 2017, and 2020. Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:16 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 20,000 | $590.05 | $11,801,000.00 |
DisclosureSEC source: 0001127602-24-015444 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,134.235 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.00 to $590.28, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:16 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 20,000 | $105.17 | $2,103,400.00 |
DisclosureSEC source: 0001127602-24-015444 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,134.235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,142 | $0.00 Strike: $399.71 | $0.00 |
DisclosureSEC source: 0000875320-24-000125 · wk-form4_1714767388.xml · derivative · entry 1 Lagarde Michel · CIK 0001518973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,142 Underlying: Common Stock · 3,142 shares Expires 2034-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:04 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 1,012.828 | $572.03 | $579,368.00 |
DisclosureSEC source: 0001127602-24-007593 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,134.235 Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:09 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 511.502 | $564.71 | $288,850.29 |
DisclosureSEC source: 0001127602-24-006826 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,147.063 F1 · balance_after: Reflects a downward adjustment of 304 shares of a performance-based restricted stock unit award granted on February 23, 2021. On February 23, 2022, the reporting person reported the acquisition of the performance-based restricted stock unit award. One-third of the shares vested on February 23, 2022, one-third of the shares vested on February 23, 2023, and the remaining one-third vested on February 23, 2024, subject to adjustment based on the Company's relative total shareholder return ("TSR") over the measurement period starting on January 1, 2021, through to December 31, 2023. As a result of the Company's relative TSR, the third tranche was adjusted downward by 15%. As such, the reporting person received 304 less shares than the amount initially reported. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:17 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 22,870 | $0.00 Strike: $418.32 | $0.00 |
DisclosureSEC source: 0001127602-24-006601 · form4.xml · derivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,870 Underlying: Common Stock · 22,870 shares Expires 2027-09-09 F2 · shares: This performance-based stock option award was granted on September 9, 2020. The Company's Compensation Committee certified on February 21, 2024 that the performance criteria related to this award were satisfied. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:17 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 14,179 | $0.00 Strike: $552.85 | $0.00 |
DisclosureSEC source: 0001127602-24-006601 · form4.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,179 Underlying: Common Stock · 14,179 shares Expires 2032-02-21 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:17 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 2,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006601 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,962.565 Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052535 · doc4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,132 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 20:17 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 131.512 | $545.19 | $71,699.03 |
DisclosureSEC source: 0001127602-23-023353 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,687.77 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.